See more : Tat Hong Equipment Service Co., Ltd. (2153.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Replimune Group, Inc. (REPL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Replimune Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- bleuacacia ltd (BLEUU) Income Statement Analysis – Financial Results
- Giant Biogene Holding Co., Ltd. (2367.HK) Income Statement Analysis – Financial Results
- Agricultural Bank of China Limited (601288.SS) Income Statement Analysis – Financial Results
- Hana 33 SPAC (475250.KQ) Income Statement Analysis – Financial Results
- Silver Spike Investment Corp. (SSIC) Income Statement Analysis – Financial Results
Replimune Group, Inc. (REPL)
About Replimune Group, Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.66M | 2.45M | 4.58M | 4.14M | 1.81M | 148.00K | 109.00K | 122.00K |
| Gross Profit | -2.66M | -2.45M | -4.58M | -4.14M | -1.81M | -148.00K | -109.00K | -122.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 174.96M | 126.53M | 79.55M | 56.75M | 38.76M | 22.17M | 13.52M | 6.94M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 23.20M | 17.44M | 8.77M | 5.71M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.81M | 50.55M | 38.77M | 23.20M | 17.44M | 8.77M | 5.71M | 2.71M |
| Other Expenses | 0.00 | -5.68M | -1.06M | -665.00K | -16.00K | 451.00K | -2.06M | 626.00K |
| Operating Expenses | 234.77M | 174.17M | 115.14M | 77.15M | 53.11M | 28.42M | 16.96M | 8.21M |
| Cost & Expenses | 234.77M | 174.17M | 115.14M | 77.15M | 53.11M | 28.42M | 16.96M | 8.21M |
| Interest Income | 16.70M | 10.01M | 390.00K | 916.00K | 2.42M | 2.59M | 288.00K | 25.00K |
| Interest Expense | 0.00 | 4.16M | 2.22M | 3.06M | 1.92M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.66M | 2.45M | 4.58M | 4.14M | 1.81M | 148.00K | 109.00K | 122.00K |
| EBITDA | -230.20M | -170.30M | -114.41M | -76.48M | -52.60M | -28.27M | -16.85M | -8.08M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -234.77M | -177.08M | -118.31M | -79.96M | -56.20M | -30.95M | -19.23M | -9.65M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.39M | 3.08M | 278.00K | -915.00K | 3.57M | 112.00K | -473.00K | 1.94M |
| Income Before Tax | -215.39M | -174.00M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | -7.70M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 408.00K | 288.00K | 1.16M | 2.40M | 1.90M | 451.00K | -2.06M | 125.00K |
| Net Income | -215.79M | -174.28M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | -7.70M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -0.64 | -0.36 |
| EPS Diluted | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -0.64 | -0.25 |
| Weighted Avg Shares Out | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.20M | 30.84M | 21.51M |
| Weighted Avg Shares Out (Dil) | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.20M | 30.84M | 30.84M |
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
2 Top Biotech Stocks From the IPO Class of 2018 to Buy Now
Biodesix Appoints Jean Franchi and Hany Massarany to Board of Directors
Marks & Spencer Transforms Workforce Scheduling for 80,000 Colleagues with JDA and Microsoft Teams
Source: https://incomestatements.info
Category: Stock Reports